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An avatar for precision cancer therapy
shumei Kato & Razelle Kurzrock
Screening patient-derived tumor cell cultures against a drug library is a promising adjunct to clinical decision-making.
Precision oncology aims to match patients to therapies on the basis of the genomic alterations in their tumors. This approach of combining molecular diagnostics with therapeutics has not only transformed the standard-of-care management for certain malignancies [1] [2] [3] , but is also integral to treatment selection in pancancer, precision medicine clinical trials 4, 5 .
In clinical practice, however, such factors as intra-and intertumor molecular heterogeneity and complexity have sometimes led to disappointingly low response rates, with responses that can be short lived. Therefore, the adoption of a more personalized N-of-one strategy that also examines the functional effects of genomic alterations may be necessary to enhance the efficacy of drug selection. In a recent issue of Nature Genetics, Lee et al. 6 demonstrate the feasibility of using drug screening of patientderived cell cultures (PDCs) to guide treatment choice for individual patients. They show that PDCs faithfully represent the molecular landscapes of the original diverse cancer types. Moreover, they exploit the PDC models to uncover new mechanisms of drug response and resistance for multiple targeted agents, and they illustrate how PDC screens can provide evidence for repurposing agents against additional cancers. Lee et al. 6 derived a large number of tumor-sphere-forming PDCs (obtained directly from surgical specimens or malignant ascites) cultured in serum-free medium across 14 cancer types from 462 patients. The PDCs were dissociated into single cells and seeded into 384-well plates (500 cells per well) and treated with a 60-drug library tar-geting major oncogenic signaling molecules (Fig. 1) . After six days of incubation, cell viability was assessed using an ATP monitoring system based on firefly luciferase. Comprehensive genomic and transcriptomic profiling demonstrated that the PDCs retained the molecular characteristics of their parental tumor tissues.
Previous studies have reported related approaches using patient-derived organoids (PDOs; self-organized, three-dimensional tissue cultures) 7 , patient-derived xenografts (PDXs; tumor fragments engrafted into immunocompromised mice) 8 or patientderived tumor cell cultures 9 . These models often (but not always) similarly recapitulate the molecular profiles of the parent tissue, as well as patient responses. The PDCs described by Lee et al. 6 differ in some ways from previous tumor cell cultures 9 , which were first grown on fibroblast monolayers and which used immunofluorescent indicators to verify cellular origin. In comparing PDCs and PDOs, PDOs have the advantage of reflecting three-dimensional architecture and may include stromal cells, which may yield a more realistic recapitulation of cell-to-cell interactions than PDCs, since the latter are grown in monolayers; even so, PDOs have the disadvantage of being more complicated to develop and maintain than PDCs.
An important benefit of the PDC strategy is that it provides a rapid and facile readout of the functional effect on drug response that results from a complex array of genomic alterations in individual patients. PDCs deliver a faster timeline than PDX animal models, which require 6 to 7 weeks to become established versus 2 to 3 weeks for PDCs, and they are more amenable to large-scale, high-throughput drug screening. In the oncology clinic, screening for drug sensitivity in a timely fashion is critical because patients may not be able to wait several weeks for a treatment to be selected. Furthermore, patient tumors may evolve during longer time windows. There are also downsides to PDCs compared with PDX models in that PDCs do not include the tumor microenvironment, which can influence important factors such as angiogenesis. Finally, many current model systems, including PDCs, PDOs and PDXs, cannot adequately recapitulate the immune system.
The 60 different targeted agents tested by Lee et al. 6 are commonly used in the clinical setting. They include inhibitors of receptor tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), and phosphoinosi tide 3-kinase (PI3K)-AKTmammalian target of rapamycin (mTOR) (PAM), as well as histone deacetylase inhibitors and more. All in all, the authors studied 27,720 drug-PDC combinations (60 drugs × 462 PDCs), which revealed diverse patterns of drug sensitivities. From this matrix, they first noted that certain cancer types are more vulnerable to certain classes of inhibitor. For example, PDCs from patients with colorectal cancer or glioblastoma were more resistant to PAM pathway inhibitors; gastric cancer PDCs were more sensitive to these inhibitors. The authors also evaluated why gastric cancer PDCs were more sensitive to modulators of the PAM pathway using an independent database (The Cancer Genome Atlas) and found the PAM pathway to be more active in gastric cancer.
Next the investigators compared drug sensitivity and gene profiling results to determine whether specific gene markers in PDCs predict sensitivity versus resistance. This analysis led to robust, clinically relevant discoveries. Among several important observations, the small-molecule drug ibrutinib, which is approved by the European Medicine Agency (Amsterdam) and the US Food and Drug Administration (FDA) for patients with chronic lymphocytic leukemia, may also be efficacious for a subgroup of glioblastoma volume 36 number 11 november 2018 nature biotechnology tors in patients with RAS alterations is associated with resistance 4, 11 . Further investigation is required in this regard, especially as Lee et al. 6 demonstrate that certain drug combinations, such as MEK inhibitors combined with EGFR inhibitors, show improved efficacy in KRASmutated colorectal cancer.
Lastly, Lee et al. 6 evaluated whether the information gained from their in vitro PDC drug screening translated into improved patient outcomes. They show, in a sophisticated (albeit retrospective) manner, that a tumor was indeed more likely to be responsive to a targeted agent when the corresponding PDCs were sensitive to that agent. Multiple clinically applicable, approved anti-cancer agents including, but not limited to, afatinib (targeting EGFR), lapatinib (targeting Her2), sunitinib (targeting PDGFR-A) and everolimus (targeting mTOR) exhibited efficacy in patients with a variety of cancer types concordant with PDC predictions. Furthermore, if the PDC model demonstrated resistance, then resistance was more likely in the patient.
The above findings suggest that PDCs are capable of identifying potential targeted therapies for patients; indeed, the authors were able to correlate their findings with patient outcomes in the clinical setting in an elegant manner. They also show that this approach can uncover new mechanisms of drug response and resistance for a wide variety of targeted agents, depending on the presence of underlying genomic markers. The approach also provides evidence to guide the repurposing of drugs, such as ibrutinib, for aggressive cancers such as glioblastomas.
Although innovative in several important ways, the study still requires validation in prospective clinical trials. Future studies should also consider interrogating the PDC system with combinations of drugs rather than monotherapies, as cancers with complex molecular genetics are likely to require more than a single drug for optimized responses.
Overall, the work of Lee et al. 6 provides compelling evidence that PDCs may provide a useful model for individualized cancer therapy. To this end, the authors are moving forward with testing PDCs in the clinical trial setting (https://clinicaltrials.gov/ct2/show/ NCT03170180), and we eagerly await the outcome of this prospective study.
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Several other important observations emerged from the authors' analyses. For instance, they established that KRAS mutations-which are present in over 20% of diverse cancers and are often considered not druggable-had high sensitivity to targeted agents, including dasatinib (targeting SRC and BCR-ABL), BYL719 (a PI3K inhibitor) and trametinib (a MEK inhibitor). This observation is important and is consistent with a case report recently published showing that a patient with Rosai-Dorfman syndrome and a KRAS mutation had a remarkable response to cobimetinib (a MEK inhibitor like trametinib) 10 . By contrast, previous results from our group suggest that the use of PI3K inhibi- PDCs. Ibrutinib is an inhibitor of Bruton's tyrosine kinase, an important pathway for this leukemia. However, the investigators discovered that ibrutinib effectively targets epidermal growth factor receptor (EGFR), which was aberrant in glioblastoma PDCs, leading to high sensitivity of this lethal malignancy to ibrutinib. These findings are consistent with previous data suggesting that ibrutinib is capable of targeting EGFR (an FDA pharmacology review found a 50% inhibitory concentration (IC 50 ) of 5.6 nM). This finding has major clinical implications for repurposing ibrutinib for patients with glioblastomas that harbor high levels of EGFR or EGFR mutations.
